Middle East crisis: Chemical, pharma manufacturers at

The Manufacturers Association of Nigeria (MAN) has issued a stark warning: the intensifying military tensions between the United States, Israel, and Iran pose an existential threat to Nigeria's chemical and pharmaceutical manufacturing base. As geopolitical instability reverberates through global supply chains, European investors with exposure to West Africa's industrial sector face mounting portfolio risk—and potentially, significant opportunity.

Nigeria's chemical and pharmaceutical industries form the backbone of West African manufacturing. The sector employs over 100,000 workers directly and supports an estimated $2.3 billion in annual output. Critically, these industries rely on imported raw materials—specialty chemicals, active pharmaceutical ingredients (APIs), and industrial catalysts—sourced heavily from the Middle East, Asia, and Europe. When Middle East tensions escalate, shipping routes face disruption, insurance premiums spike, and lead times stretch unpredictably. For manufacturers operating on thin margins in emerging markets, these shocks translate into production halts.

The current crisis presents three immediate risks. First, the Strait of Hormuz—through which approximately 20% of global petroleum and petrochemical trade flows—remains vulnerable to blockade or attack. Any disruption would spike crude oil and chemical feedstock prices within 48 hours, cascading through Nigeria's manufacturing cost structure. Second, freight insurance and shipping availability tighten during geopolitical crises. MAN members already report 30-40% increases in logistics costs year-on-year; Middle East escalation could push this higher. Third, currency volatility follows geopolitical shock. The Nigerian naira, already under pressure from central bank policy uncertainty, could weaken further against the euro and dollar, making imported inputs substantially more expensive.

For pharmaceutical manufacturers specifically, the risk is acute. Nigeria's domestic API production capacity remains minimal—approximately 15-20% of national requirements. The remainder comes from imports, particularly from India, China, and increasingly from Middle Eastern manufacturers. Production stoppages in supplying countries, combined with shipping delays, could create critical drug shortages within 6-8 weeks. The Nigerian healthcare system, already stretched, would face pressure to approve emergency imports at premium prices or ration supplies.

However, this crisis also reveals an investment thesis. Nigeria's government has signaled commitment to domestic pharmaceutical manufacturing through the National Drug Distribution Guidelines and ongoing tariff support. European investors with manufacturing or import-distribution assets in Nigeria should prepare for two scenarios: (1) short-term margin compression and working capital stress, requiring liquidity buffers; and (2) medium-term consolidation, where well-capitalized operators acquire distressed competitors and capture market share.

The broader implication: Middle East instability is accelerating Africa's industrial localization imperative. European firms that help Nigerian manufacturers reduce import dependency—through technology partnerships, API localization, or supply chain financing—will find receptive partners and policy tailwinds. The crisis is not just a risk; it is an accelerant for structural change.

For investors already holding positions in Nigerian manufacturing, vigilance on supply chain exposure is essential. For those considering entry, the valuation dislocations created by near-term shock may present compelling entry points for long-term holders with patience and local expertise.

---